PBA
BIIB icon

Paradigm Biocapital Advisors’s Biogen BIIB Stock Holding History

Paradigm Biocapital Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-349,593
Closed -$97.2M – 32
2023
Q1 		$97.2M Buy
349,593
+110,821
+46% +$30.7M 9.21% 1
2022
Q4 		$66.1M Buy
238,772
+84,167
+54% +$23.8M 7.76% 2
2022
Q3 		$41.3M Buy
+154,605
New +$32.8M 5.5% 6

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Paradigm Biocapital Advisors's BIIB Position: Q2 2023 in Review

Paradigm Biocapital Advisors sold out of Biogen (BIIB) in Q2 2023, closing a stake of 349,593 shares — an estimated $97.2M sold.

Paradigm Biocapital Advisors first reported a position in BIIB in Q3 2022 and held it in 3 quarters. The position peaked at $97.2M in Q1 2023. 1,008 funds tracked by Wall St. Rank hold BIIB as of Q2 2023.

  • Paradigm Biocapital Advisors reported no remaining Biogen position as of Q2 2023 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 349,593 Biogen shares in Q2 2023, an estimated $97.2M.
  • Paradigm Biocapital Advisors first reported a position in Biogen in Q3 2022 and held it in 3 quarters.
  • Paradigm Biocapital Advisors's Biogen position peaked at $97.2M in Q1 2023.
  • 1,008 funds tracked by Wall St. Rank held Biogen as of Q2 2023.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.